0001601830-24-000023.txt : 20240314 0001601830-24-000023.hdr.sgml : 20240314 20240314192845 ACCESSION NUMBER: 0001601830-24-000023 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240312 FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Secora Michael CENTRAL INDEX KEY: 0001855980 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 24751994 MAIL ADDRESS: STREET 1: C/O RECURSION PHARMACEUTICALS STREET 2: 41 S. RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 wk-form4_1710458910.xml FORM 4 X0508 4 2024-03-12 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001855980 Secora Michael C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 Chief Financial Officer 1 Class A Common Stock 2024-03-12 4 M 0 37500 2.22 A 1216679 D Class A Common Stock 2024-03-12 4 S 0 25000 10.455 D 1191679 D Class A Common Stock 2024-03-13 4 M 0 37500 2.22 A 1229179 D Class A Common Stock 2024-03-13 4 S 0 25000 11.0326 D 1204179 D Stock Option (Right to Buy) 2.22 2024-03-12 4 M 0 37500 0 D 2030-03-03 Class A Common Stock 37500 922635 D Stock Option (Right to Buy) 2.22 2024-03-13 4 M 0 37500 0 D 2030-03-03 Class A Common Stock 37500 885135 D Stock Option (Right to Buy) 2.22 2030-03-03 Class A Common Stock 0 685177 D Stock Option (Right to Buy) 11.14 2032-02-04 Class A Common Stock 0 116684 D Stock Option (Right to Buy) 11.14 2022-02-04 2032-02-04 Class A Common Stock 0 3914 D Stock Option (Right to Buy) 8.55 2033-02-01 Class A Common Stock 0 404857 D Stock Option (Right to Buy) 10.09 2034-02-09 Class A Common Stock 0 348380 D Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. This transaction was executed in multiple trades at prices ranging from $10.21 to $10.67 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $10.98 to $11.33 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/ Jonathan Golightly, attorney-in-fact 2024-03-14